AIM IMMUNOTECH INC (AIM)

US00901B1052 - Common Stock

0.2569  0 (-1.61%)

After market: 0.2572 +0 (+0.12%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AIM IMMUNOTECH INC

NYSEARCA:AIM (11/4/2024, 8:04:00 PM)

After market: 0.2572 +0 (+0.12%)

0.2569

0 (-1.61%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-35.77%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap16.27M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AIM Daily chart

Company Profile

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 26 full-time employees. The company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Company Info

AIM IMMUNOTECH INC

2117 Sw Highway 484

Ocala FLORIDA 34473

P: 13524487797

CEO: Thomas K. Equels

Employees: 27

Website: https://aimimmuno.com/

AIM News

News Image16 hours ago - AIM ImmunoTech Inc.AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
News Imagea month ago - AIM ImmunoTech Inc.AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

Live webcast fireside chat on Wednesday, October 16th at 12:30 PM ET...

News Imagea month ago - AIM ImmunoTech Inc.AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States...

News Imagea month ago - AIM ImmunoTech Inc.AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET...

News Image2 months ago - AIM ImmunoTech Inc.AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue

Company is planning a follow-up clinical trial with a focused subject population of moderate-to-severe Post-COVID-related fatigue...

News Image3 months ago - AIM ImmunoTech Inc.AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary...

AIM Twits

Here you can normally see the latest stock twits on AIM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example